The Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. Adam Glanzman | Bloomberg | Getty Images Moderna on Thursday reported second-quarter revenue that beat expectations but …
The Food and Drug Administration on Monday approved Merck‘s new vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection …
A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022. Hannah Mckay | Reuters The Food and Drug Administration on Friday expanded the approval of GSK‘s respiratory syncytial virus …
Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. Matthew Childs | Reuters LONDON — Shares of British pharmaceuticals giant GSK plunged 9% …
Nikos Pekiaridis | Lightrocket | Getty Images The Food and Drug Administration on Friday approved Moderna’s vaccine for respiratory syncytial virus for adults ages 60 and above, the company’s second-ever …
Nikos Pekiaridis | Lightrocket | Getty Images Moderna on Friday said the Food and Drug Administration has delayed the approval of its vaccine for respiratory syncytial virus to the end …
A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. Lee Smith | Reuters The Federal Trade Commission on Tuesday said it …
Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are …
A woman using an inhaler. BSIP | Universal Images Group | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign …
Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Pfizer‘s vaccine against respiratory syncytial virus maintained protection for older adults across two full seasons of the disease in an …